Cellular Dynamics International Announces Launch of CIRM hPSC Repository and First 300 iPSC Lines
Cellular Dynamics International (CDI), a FUJIFILM company since March of 2015, announced news today that has reverberated throughout the stem cell community, suggesting hope and progress for the future of stem cell research.
Since that time, CDI has received tissue samples taken from patients with conditions that include eleven common diseases and disorders. Targeted conditions include: Alzheimer’s disease, autism, cardiovascular disease, liver conditions, cerebral palsy, respiratory conditions, diseases of the eye, and more. Using these tissues samples, CDI has been working over the past two years to generate iPS cells through an episomal (“footprint-free”) reprogramming method first developed by the company.
Today, Cellular Dynamics International announced that their efforts have been effective and their financial support from CIRM well-deserved. In a press release distributed today through their corporate site, Cellular Dynamics announced the launch of the world’s largest publicly available stem cell bank, the California Institute for Regenerative Medicine (CIRM) hPSC Repository and the availability of the first 300 induced pluripotent stem cell (iPSC) lines.
RFA 12-04: CIRM hPSC Repository Award
As of today, September 1, 2015, the CIRM hPSC Repository is offering the first 300 iPSC lines generated through the Cellular Dynamics and Coriell Institute partnership, including iPS cells derived from healthy and diseased donors and donors. Cellular Dynamics International is now stating that the number of available iPS Clines will increase to 750 by February of 2016 and will continue growth from there. For researchers seeking undifferentiated iPSC lines, they can access them through the Coriell Institute for Medical Research.
The CIRM hPSC Repository was conceived and created through award number FRA 12-04, one of three separate RFAs (RFAs 12-02, 12-03 and 12-04) that were released as part of a CIRM human induced pluripotent stem cell (hiPSC) initiative. As stated in a release by CIRM, the primary goal of this Initiative is to “generate and ensure the availability of high quality disease-specific hiPSC resources for disease modeling, target discovery and drug discovery and development for prevalent, genetically complex diseases.” More specifically, the RFA 12-04 award will “support a single qualified organization that will create a repository for high quality, disease-specific, research grade human pluripotent stem cell (hPSC) lines generated in California to enable their reliable distribution worldwide.”
The full press release distributed today by Cellular Dynamics International, a FUJIFILM company, is available here:
Future Posts
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data. To learn more about induced pluripotent stem cell (iPSC) industry trends and events, view the “Compete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report.”